DTX-105

DTX-105 is a preclinical-stage small molecule therapeutic candidate being developed by Dual Therapeutics (also known as Dualitas) for the treatment of gastrointestinal (GI) disorders, specifically inflammatory bowel disease (IBD). Dual Therapeutics specializes in the development of "dual-action" small molecules that address complex disease biology by simultaneously targeting multiple signaling pathways or activating tumor suppressors such as Protein Phosphatase 2A (PP2A). While the specific molecular target of DTX-105 has not been publicly disclosed in the company's pipeline summaries, the program leverages the sponsor's platform for multi-targeted intervention in inflammatory and oncological conditions. The asset is currently undergoing preclinical evaluation to support potential future clinical development for IBD.

Other names

DTX105DTX-105DTX 105